FDA places partial hold on Biohaven's ion channel drug

The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday. An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety ...